Rocket pharmaceuticals, inc. (RCKT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Jun'14Mar'14
Revenue

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

16,957

14,668

14,829

13,989

15,137

23,690

13,065

10,772

5,743

4,919

4,894

2,819

2,285

-16,498

8,412

6,465

7,615

5,919

3,612

1,954

1,069

1,862

1,550

General and administrative

7,163

4,981

4,336

4,403

3,808

2,856

2,268

4,100

8,662

1,737

1,831

702

585

-5,568

2,311

2,315

2,522

2,309

1,825

1,728

1,980

332

162

Total operating expenses

24,120

19,649

19,165

18,392

18,945

26,546

15,333

14,872

14,405

6,656

6,725

3,521

2,870

-

-

-

-

-

-

-

-

-

-

Loss from operations

-24,120

-19,649

-19,165

-18,392

-18,945

-26,546

-15,333

-14,872

-14,405

-6,656

-6,725

-3,521

-2,870

22,066

-10,723

-8,780

-10,137

-8,228

-5,437

-3,682

-3,049

-2,194

-1,712

Amount of research and development income claimed from tax credit against the General Corporation Tax and Unincorporated Business Tax during the period.

0

0

0

0

250

0

0

0

186

-192

0

192

192

-

-

-

-

-

-

-

-

-

-

Interest expense

1,573

1,344

1,466

1,544

1,604

2,073

1,176

1,363

1,427

0

0

0

0

-

525

-

-

0

192

564

474

248

243

Interest and other income net

967

834

979

1,000

601

514

420

468

288

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on investments

62

304

368

256

247

786

0

0

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

2

0

0

-

120

96

69

-

33

-

-

-

-

Other income / (expense) net

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-3,716

0

-683

-

-

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-267

405

193

Change in fair value of Convertible Bridge Notes redemption rights derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-480

-

-

Change in fair value of 2020 Convertible Notes derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-46,649

1,859

1,997

-

-

Net loss

-24,664

-19,855

-19,284

-18,680

-19,451

-27,319

-16,089

-15,767

-15,343

-6,848

-6,723

-3,329

-2,678

22,307

-11,128

-8,684

-10,068

-8,172

-55,961

-2,387

-1,462

-2,847

-2,148

Net loss per share attributable to common stockholders - basic and diluted (in dollars per share)

-0.45

-0.39

-0.38

-0.38

-0.43

-0.67

-0.40

-0.40

-0.42

-1.01

-0.99

-0.49

-0.39

0.01

-0.41

-0.33

-0.38

-0.88

-2.48

-0.15

-0.21

-3.81

-3.08

Weighted-average common shares outstanding - basic and diluted (in shares)

54,883

51,286

50,364

49,267

45,122

41,989

39,900

39,483

36,137

6,795

6,795

6,795

6,795

-52,642

26,930

26,623

26,423

26,667

22,573

16,327

7,677

1,020

1,020